Girke W, Lieske V
Pharmakopsychiatr Neuropsychopharmakol. 1977 Sep;10(5):281-5. doi: 10.1055/s-0028-1094549.
Five patients suffering from choreo-athetotic syndromes of different genesis were treated with the benzodiazepine-derivative Ro 06-9098/000 (7-Nitro-1(methylmethoxy)-1,3-dihydro-5-phenyl-2 H-1,4-benzodiazepin-2-one). The existing hyperkinesias could be well influenced in four cases of male patients, sufficiently in one case of a female patient. The sedative effect, accompanied by a muscle hypotonia appearing simultaneously under the medication, did not represent and essential limiting factors at the chosen dose of 5--20 mg/die. The observed successes in therapy point at the result and effect of benzodiazepine derivatives on extra-pyramidalmotoric hyperkinesias which got little attention until now.
对5例患有不同病因的舞蹈手足徐动症综合征的患者使用苯二氮䓬衍生物Ro 06-9098/000(7-硝基-1-(甲基甲氧基)-1,3-二氢-5-苯基-2H-1,4-苯并二氮杂䓬-2-酮)进行治疗。在4例男性患者中,现有的运动亢进得到了很好的改善,在1例女性患者中得到了充分改善。在5-20mg/日的选定剂量下,药物治疗时伴随出现的镇静作用以及同时出现的肌张力减退并不构成重要的限制因素。观察到的治疗成功表明苯二氮䓬衍生物对锥体外系运动亢进有疗效,而这一点至今很少受到关注。